MYL : NASDAQ : Health Technology
$41.45 up 0.17 | 0.41%
Today's Range: 41.16 - 42.0
Avg. Daily Volume: 5901700.0
02/23/18 - 4:00 PM ET

Financial Analysis


MYLAN NV's gross profit margin for the third quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. Even though sales decreased, the net income has increased. MYLAN NV has weak liquidity. Currently, the Quick Ratio is 0.82 which shows a lack of ability to cover short-term cash needs. The company's liquidity has increased from the same period last year.

During the same period, stockholders' equity ("net worth") has increased by 12.38% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY17 Q3 FY16
Net Sales ($mil)2987.13057.1
EBITDA ($mil)894.5977.8
EBIT ($mil)451.4531.9
Net Income ($mil)88.3-119.8


Balance Sheet Q3 FY17 Q3 FY16
Cash & Equiv. ($mil)871.11413.4
Total Assets ($mil)35818.936538.5
Total Debt ($mil)14715.215817.4
Equity ($mil)13291.611827.3


Profitability Q3 FY17 Q3 FY16
Gross Profit Margin55.3857.55
EBITDA Margin29.9431.98
Operating Margin15.1117.4
Sales Turnover0.330.28
Return on Assets2.420.7
Return on Equity6.532.17
Debt Q3 FY17 Q3 FY16
Current Ratio1.460.83
Debt/Capital0.530.57
Interest Expense124.5112.2
Interest Coverage3.634.74


Share Data Q3 FY17 Q3 FY16
Shares outstanding (mil)536.35535.07
Div / share0.00.0
EPS0.16-0.23
Book value / share24.7822.1
Institutional Own % n/a n/a
Avg Daily Volume6153466.05993669.0

Valuation


HOLD. The current P/E ratio indicates a significant discount compared to an average of 103.47 for the Pharmaceuticals industry and a value on par with the S&P 500 average of 25.51. For additional comparison, its price-to-book ratio of 1.68 indicates a significant discount versus the S&P 500 average of 3.26 and a significant discount versus the industry average of 8.06. The price-to-sales ratio is below the S&P 500 average and is well below the industry average, indicating a discount. Upon assessment of these and other key valuation criteria, MYLAN NV proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
MYL 25.87 Peers 103.47   MYL 11.64 Peers 45.14

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

MYL is trading at a significant discount to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

MYL is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
MYL 7.71 Peers 14.27   MYL 0.07 Peers 2.43

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

MYL is trading at a significant discount to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

MYL trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
MYL 1.68 Peers 8.06   MYL 215.68 Peers -316.45

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

MYL is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

MYL is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
MYL 1.87 Peers 18.73   MYL 15.89 Peers 37.34

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

MYL is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

MYL significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades